Table 3.
Distribution of clinically relevant variables and outcomes before and after propensity score matching in patients with or without LT3S.
| Variables | Pre-PSM |
Post-PSM |
||||
|---|---|---|---|---|---|---|
| Normal fT3 (n = 958) |
LT3S (n = 204) |
p-Value | Normal fT3 (n = 197) |
LT3S (n = 197) |
p-Value | |
| Baseline data | ||||||
| Male, n (%) | 742 (77.4) | 114 (55.8) | <.001 | 97 (49.2) | 98 (49.7) | .976 |
| Age, years | 54.5 ± 11.5 | 61.0 ± 11.6 | <.001 | 61.0 ± 10.6 | 61.0 ± 11.4 | .989 |
| STEMI, n (%) | 368 (38.4) | 88 (43.1) | .042 | 85 (43.1) | 84 (42.6) | .845 |
| Hypertension, n (%) | 497 (51.8) | 122 (59.8) | .039 | 116 (58.8) | 119 (60.4) | .758 |
| Diabetes, n (%) | 139 (14.5) | 44 (21.5) | .012 | 33 (16.7) | 43 (21.8) | .202 |
| LVEF, % | 60.9 ± 7.2 | 58.6 ± 8.2 | .001 | 60.3 ± 5.9 | 58.7 ± 8.3 | .002 |
| hs-CRP, mg/L | 2.0 (0.9, 5.3) | 4.3 (1.5, 9.6) | <.001 | 1.9 (0.8, 4.6) | 4.0 (1.4, 9.4) | <.001 |
| NT-proBNP, pg/mL | 363 (109, 677) | 452 (138, 940) | .002 | 382 (104, 675) | 447 (135, 936) | .013 |
| Peak TnI, ng/mL | 3.1 (0.5, 5.9) | 5.6 (1.2, 8.7) | .006 | 3.7 (0.8, 6.4) | 5.8 (1.1, 8.9) | .025 |
| CV outcomes | ||||||
| MACE | 124 (12.9) | 40 (19.6) | .013 | 22 (11.1) | 38 (19.2) | .025 |
| Risk of MACE | 1 (reference) | 1.50 (1.03–2.18) | .037 | 1 (reference) | 1.53 (1.02–2.65) | .042 |
Clinically relevant variables and outcomes were compared before and after propensity score matching (PSM). Demographics and baseline comorbidities became comparable after PSM. The risk of MACE was adjusted by age, sex, MI type (NSTEM or STEMI), hypertension, diabetes, dyslipidemia, LVEF, NT-proBNP, peak TnI and hs-CRP, and expressed as HR (95% CI).
STEMI: ST-segment elevation myocardial infarction; LVEF: left ventricular ejection fraction; hs-CRP: high-sensitive C-reactive protein; NT-proBNP: N-terminal pro-B-type natriuretic peptide; TnI: Troponin I; MACE: major adverse cardiovascular events; LT3S: low triiodothyronine syndrome.